1. Scrip
  2. >>Business

Roche "Disappointed" By ASCO Focus, Progressing CEA-CD3 Bispecific

 
• By Sten Stovall

Roche CEO Severin Schwan says analysts at ASCO missed a key APHINITY message on Herceptin follow-on Perjeta, and that the Swiss group will swiftly progress its CEA-CD3 bispecific to pivotal studies based on data presented there.

Schwan_Severin_1200x675
Severin Schwan "Disappointed" By ASCO APHINITY Reactions • Source: Roche AG

Roche's Austrian CEO Severin Schwan has a reputation for being mild-mannered, diplomatic and very precise – so when he says he's "disappointed" by ASCO's reception of a key product presentation – namely the Phase III APHINITY trial examining use of Perjeta (pertuzumab), Herceptin (trastuzumab) and chemotherapy together in the adjuvant treatment of breast cancer – there is a loud message underneath.

"I am disappointed," he told Scrip when discussing the group's APHINITY presentation at the just-ended ASCO event in Chicago, during...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.